Simon P. Fletcher

4.5k total citations · 2 hit papers
59 papers, 3.0k citations indexed

About

Simon P. Fletcher is a scholar working on Epidemiology, Hepatology and Immunology. According to data from OpenAlex, Simon P. Fletcher has authored 59 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Epidemiology, 36 papers in Hepatology and 15 papers in Immunology. Recurrent topics in Simon P. Fletcher's work include Hepatitis B Virus Studies (40 papers), Hepatitis C virus research (34 papers) and Liver Disease Diagnosis and Treatment (21 papers). Simon P. Fletcher is often cited by papers focused on Hepatitis B Virus Studies (40 papers), Hepatitis C virus research (34 papers) and Liver Disease Diagnosis and Treatment (21 papers). Simon P. Fletcher collaborates with scholars based in United States, France and Germany. Simon P. Fletcher's co-authors include Richard J. Jackson, Tatyana V. Pestova, Ivan N. Shatsky, Christopher U.T. Hellen, Rudolf K. Beran, Christine M. Livingston, Michel Strubin, Congrong Niu, D R Averett and Fabien Abdul and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Genes & Development.

In The Last Decade

Simon P. Fletcher

57 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initation of hepatitis C and classical swine fever virus RNAs

1998 607 citations Simon P. Fletcher et al. profile →
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

2016 398 citations Rudolf K. Beran, Christine M. Livingston et al. profile →

Peers

Simon P. Fletcher

EPIDE

HEPAT

IMMUN

CCM

Geneviève Inchauspé France

René Rijnbrand United States

Donna M. Tscherne United States

Zongdi Feng United States

Alissa M. Lancaster United States

David R. McGivern United States

J H Ou United States

Kevin L. McKnight United States

Udayan Chatterji United States

Michael D. Robek United States

Geneviève Inchauspé France

Simon P. Fletcher

2.5k ×1.4

EPIDE

2.7k ×1.8

HEPAT

704 ×0.8

795 ×1.1

IMMUN

245 ×0.5

CCM

Citations per year, relative to Simon P. Fletcher Simon P. Fletcher (= 1×) peers Geneviève Inchauspé

Countries citing papers authored by Simon P. Fletcher

Since Specialization

Citations

This map shows the geographic impact of Simon P. Fletcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon P. Fletcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon P. Fletcher more than expected).

Fields of papers citing papers by Simon P. Fletcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon P. Fletcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon P. Fletcher. The network helps show where Simon P. Fletcher may publish in the future.

Co-authorship network of co-authors of Simon P. Fletcher

This figure shows the co-authorship network connecting the top 25 collaborators of Simon P. Fletcher. A scholar is included among the top collaborators of Simon P. Fletcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon P. Fletcher. Simon P. Fletcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lens, Sabela, Alice R. Burton, Maëlle Locatelli, et al.. (2025). Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal. Gut. gutjnl–2024.

Johnston, Christine, et al.. (2025). Association between herpes simplex virus type 1 and the risk of Alzheimer’s disease: a retrospective case–control study. BMJ Open. 15(5). e093946–e093946. 5 indexed citations

Allweiss, Lena, et al.. (2024). Pegylated interferon-alpha treatment in vivo potently reduces all HDV markers in primary human hepatocytes undergoing cell division. Zeitschrift für Gastroenterologie. 62(1). e60–e60. 1 indexed citations

Pan, David Z., Cameron M. Soulette, Abhishek Aggarwal, et al.. (2024). Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B. Gut. 74(4). 628–638. 4 indexed citations

Yu, Mei, Maura Dandri, Guofeng Cheng, et al.. (2024). Rapid and Reliable Protein-Free HBV DNA Extraction and Sensitive Branched DNA Southern Blot Assay. Methods in molecular biology. 2837. 113–124. 1 indexed citations

Allweiss, Lena, Barbara Testoni, Yu Mei, et al.. (2023). Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure. Gut. 72(5). 972–983. 43 indexed citations

Schmidt, Sarah, Stéphane Daffis, Adrian Tomkinson, et al.. (2023). Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus–Specific CD8 T-Cell Responses and High Anti–Hepatitis B Surface Antigen Titers. The Journal of Infectious Diseases. 229(4). 1077–1087. 4 indexed citations

Aggarwal, Abhishek, Pamela M. Odorizzi, Jens Brodbeck, et al.. (2022). Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Reports. 5(4). 100664–100664. 17 indexed citations

Gane, Edward, P. Rod Dunbar, Anna E. S. Brooks, et al.. (2022). Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. Journal of Hepatology. 78(3). 513–523. 25 indexed citations

10.

Allweiss, Lena, Katja Giersch, Tassilo Volz, et al.. (2021). Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo. Gut. 71(2). 372–381. 60 indexed citations

11.

Salimzadeh, Loghman, Nina Le Bert, Charles‐Antoine Dutertre, et al.. (2018). PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection. Journal of Clinical Investigation. 128(10). 4573–4587. 198 indexed citations

12.

Lucifora, Julie, Marc Bonnin, Ludovic Aillot, et al.. (2018). Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Scientific Reports. 8(1). 5390–5390. 61 indexed citations

13.

Niu, Congrong, Li Li, Stéphane Daffis, et al.. (2017). Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. Journal of Hepatology. 68(5). 922–931. 71 indexed citations

14.

Li, Li, Vivian Barry, Stéphane Daffis, et al.. (2017). Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells. Journal of Hepatology. 68(5). 912–921. 43 indexed citations

15.

Menne, Stephan, Daniel B. Tumas, Dalal Aldeghaither, et al.. (2015). Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. Journal of Hepatology. 62(6). 1237–1245. 167 indexed citations

16.

Allweiss, Lena, Tassilo Volz, Marc Lütgehetmann, et al.. (2013). Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. Journal of Hepatology. 60(3). 500–507. 70 indexed citations

17.

Fletcher, Simon P., Daniel J. Chin, Yongmei Ji, et al.. (2012). Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 56(3). 820–830. 78 indexed citations

18.

Fletcher, Simon P., Lisa Bauman, Marina G. Sergeeva, et al.. (2009). 944 PK/PD ASSESSMENT OF A PHASE 1 HEALTHY VOLUNTEER STUDY WITH ANA773, AN ORAL PRODRUG OF A TLR7 AGONIST FOR THE TREATMENT OF HCV. Journal of Hepatology. 50. S343–S343. 1 indexed citations

19.

Tan, Joyce T., et al.. (2007). The active metabolite of the TLR7 agonist prodrug ANA773 activates anti-tumor activity by natural killer cells. Cancer Research. 67. 3556–3556. 1 indexed citations

20.

Horsmans, Yves, Thomas Berg, Jean‐Pierre Desager, et al.. (2005). Isatoribine, an Agonist of TLR7, Reduces Plasma Virus Concentration in Chronic Hepatitis C Infection *. Hepatology. 42(3). 724–731. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact